Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + brachytherapy for metastatic, persistent, or recurrent cervical cancer
ChiCTR2000038689Phase 2Not yet recruiting
- Sponsor
- Jiang Ping
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in Cervical Cancer (CC), sponsored by Jiang Ping. Primary endpoint: Objective response rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000038689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038689.